A decanuclear oxomolybdenum(V,VI) cluster with 4-isopropylpyridine

The title centrosymmetric cluster octakis(4-iso­propyl­pyridine-N)-di-μ₄-oxo-hexa-μ₃-oxo-octa-μ₂-oxo-deca­oxo­octa­molyb­denum(V)­dimolybdenum(VI), [Mo₁₀O₂₆(C₈H₁₁N)₈], consists of ten Mo atoms connected together by bridging oxo groups. Pentavalent Mo atoms are linked into four Mo₂^V pairs by metal–metal single bonds with lengths of 2.5637 (6) and 2.6132 (6) Å.     

Three-dimensional helical coordination networks of a hexanuclear manganese metallamacrocycle as a helical tecton

We report on helical coordination networks that were prepared using a hexanuclear manganese metallamacrocycle as a helical tecton. We were able to prepare the three-dimensional helical coordination networks using a hexanuclear manganese metallamacrocycle, [Mn(6)(lshz)(6)], as a helical tecton, where N-lauroyl salicylhydrazide (H(3)lshz) was used as the primary building unit to generate the helical tecton as a secondary building unit. While the 4(1)/4(3) screw symmetry-linked helical coordination network was obtained when the primary building units had an N-acetyl group, both the 3(1)/3(2) screw symmetry-linked and the 4(1)/4(3) screw symmetry-linked helical coordination networks were obtained simultaneously in the same batch when the primary building unit had a long alkyl N-lauroyl group at the N-acetyl site.     

Transformations of phenylhydrazones of dialkyl 2‐oxo‐propane‐1,3‐dicarboxylate and of ethyl acetoacetate in concentrated sulfuric acid

The hydrazones 3a,b , prepared from phenylhydrazine ( 1 ) and dialkyl 2‐oxopropane‐1,3‐dicarboxylate ( 2a,b ) were converted in concentrated sulfuric acid at ?5 °C into a mixture of alkyl (3‐carboxyindol‐2‐yl)acetates ( 5a,b ), and ethyl (5‐ethoxy‐1‐phenyl‐1H‐pyrazol‐3‐yl)acetate 6 . The hydrazone 8 , prepared from 1 and ethyl acetoacetate ( 7 ) was transformed under the same conditions into a mixture of five compounds: ethyl 2‐methylindol‐3‐carboxylate ( 9 ), 2‐methylindol‐3‐carboxylic acid ( 10 ), 2‐methylindol ( 11 ), 5‐ethoxy‐3‐methyl‐1‐phenyl‐1H‐pyrazole ( 12 ), and 3‐methyl‐1‐phenyl‐1H‐pyrazol‐5‐one ( 13 ).     

The synthesis of β-heteroarylamino-α,β-dehydro-α-amino acid and β-heteroarylamino-α-amino acid derivatives

From heteroarylaminomethyleneoxazolones 4 , obtained from N-heteroarylformamidines 2 and 2-phenyl-5-oxo-4,5-dihydro-1,3-oxazole ( 3 ), the following β-heteroarylamino-α,β-dehydro-α-amino acid derivatives were prepared: methyl 8 and ethyl esters 9 , amides 10 and 11 , hydrazides 12 , and azides 15 . By catalytic hydrogenation the compounds 4 were converted into β-heteroarylamino substituted amides 18 and β-heteroarylamino-α-amino acids 20 .     

Transformations of Methyl 2‐[(E)‐2‐(Dimethylamino)‐1‐(methoxycarbonyl)ethenyl]‐1‐methyl‐1H‐indole‐3‐carboxylate

A simple and efficient synthesis of novel 2‐heteroaryl‐substituted 1H‐indole‐2‐carboxylates and γ‐carbolines, compounds 1 – 3 , from methyl 2‐(2‐methoxy‐2‐oxoethyl)‐1‐methyl‐1H‐indole‐3‐carboxylate ( 4 ) by the enaminone methodology is presented.     

A non-aqueous organometallic route to highly monodispersed copper nanoparticles using [Cu(OCH(Me)CH2NMe2)2

Good quality, highly monodispersed capped copper metal nanoparticles have been synthesised in a non-hydrolytic approach using thermal decomposition of the Cu(II) precursor [Cu(OCH(Me)CH2NMe2)2] in a hot coordinating solvent without further reducing agents; the copper nanoparticles have been characterised by optical spectroscopy (UV/VIS), electron microscopy (TEM), electron diffraction (SAED), and dynamic light scattering (DLS).     

A dimeric cobalt(II)–suberate complex with 3‐amino­pyridine

The title complex, μ‐octane‐1,8‐dioato‐bis[bis(3‐aminopyridine)chloro(methanol)cobalt(II)], [Co₂(C₈H₁₂O₄)Cl₂(C₅H₆N₂)₄(CH₄O)₂], is located on a crystallographic centre of inversion. The coordination around each of the Co centres is distorted octa­hedral, involving two N, three O and one Cl atom. Discrete dimers are connected in a three‐dimensional arrangement through N—H⋯O, N—H⋯Cl and O—H⋯O hydrogen‐bond inter­actions.     

Expert system for solving problems in carbon-13 nuclear magnetic resonance spectroscopy

The expert system CARBON is built around a knowledge base consisting of spectra/structure correlations, tables of data, mathematical formulae and graph-theory procedures and on a data base of 2500 assigned ¹³C-NMR spectra. The built-in knowledge enables the user to obtain suggestions for solutions to problems of different types arising in ¹³C-NMR spectroscopy. Use of the system is facilitated by appropriate command files, large on-line help files, and user-friendly dialogue. The system can be used with spectrometries other than ¹³C-NMR and in other fields concerned with correlations between chemical structures and properties.     

Analysis of LK-157 in Plasma by LC–MS–MS: Application to Studies of Pharmacokinetics and Degradation Pathways in Rats and Dogs

Multiple-species plasma-stability testing and pharmacokinetic studies in rats and dogs were performed on LK-157, a novel 10-ethylidene tricyclic carbapenem and potent inactivator of β-lactamases of classes A, C, and D. An LC–MS–MS method was developed and validated for analysis of LK-157 in rat and dog plasma. Separation was achieved on a C₁₈ column by gradient elution. The lower limit of quantification for LK-157 in plasma was 50 ng mL^?1. Intra-day and inter-day precision were <12.5 and <11.8%, respectively. When degradation of LK-157 was assessed in buffer solutions and in rat, dog, and human plasma, the compound was found to be stable in pH 7.0–9.0 phosphate buffer for 24 h at room temperature, and in human plasma for 60 min at 37 °C. The stability of LK-157 was species-dependent. Results from study of in vitro metabolism showed that the enzymes liver cytochrome P450 and uridine diphosphate glycosyltransferase do not metabolize LK-157. LC–MS–MS was also successfully applied to a pharmacokinetic study. The pharmacokinetics of LK-157 after bolus intravenous administration (10 mg kg^?1) to Wistar rats and Beagle dogs was described by a two-compartment pharmacokinetic model. Human pharmacokinetic data were extrapolated from dog pharmacokinetic data. The extrapolated human terminal-phase half-life of LK-157 was 2.3 h. Stability and pharmacokinetic data for LK-157 are in agreement with results for other inactivators of β-lactamases.